Iceland· IS-EU/1/21/1595/001-002
ASPAVELI
A pegcetacoplan product containing pegcetacoplanum inn, registered in Iceland by *Swedish Orphan Biovitrum AB (publ). The same ATC class is registered in 12 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Pegcetacoplan is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AJ03 (pegcetacoplan), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Pegcetacoplan · ATC L04AJ03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Pegcetacoplanum INN
- Manufacturer
- *Swedish Orphan Biovitrum AB (publ)
- Country
- Iceland (IS)
- ATC code
- L04AJ03
- ATC class
- Pegcetacoplan
- Defined daily dose
- 0.3 g, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 2
2 priced- ean4984051 hgl x1 pakkiISK 488341
- ean5046598 hgl x1 pakkiISK 3847678
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pegcetacoplan in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaASPAVELISwedish Orphan Biovitrum AB (publ), Stockholm
- BelgiumAspaveli 1080 mgSwedish Orphan Biovitrum (Publ)
- SpainASPAVELI 1080 MG SOLUCION PARA PERFUSIONSwedish Orphan Biovitrum Ab (Publ)
- NorwayAspaveliApellis Ireland Limited
- SwedenASPAVELI 1080 mg Infusionsvätska, lösningSwedish Orphan Biovitrum AB (publ)
- United StatesEmpaveliApellis Pharmaceuticals, Inc.
- SwitzerlandAspaveli
- FinlandASPAVELISwedish Orphan Biovitrum AB (publ)
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Aspaveli
- Norway · Aspaveli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/552b9150-f144-4a74-a03e-64e7aa4d6a9b GET /v1/drugs/552b9150-f144-4a74-a03e-64e7aa4d6a9b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslislyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "L04AJ03",
"marketed": true,
"strength": "1080 mg",
"ma_number": "EU/1/21/1595/001-002",
"substance": "Pegcetacoplanum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í nýrnasjúkdómum og blóðsjúkdómum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "44543"
}See everything about pegcetacoplan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.